Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.
Antimalarial protects against metabolic syndrome, countering steroid effects.
No change in interferon signature in vitamin D-deficient patients, those with vitamin D repletion.
Increased risk of systemic lupus erythematosus, lupus nephritis with copy number loss, not gain.
Urinary red blood cells undermine a composite prediction of renal outcome.
New study also provides evidence that an early proteinuria decrease is a strong predictor of good long-term outcome.
Minority race/ethnicity and lack of private insurance associated with inadequate care in U.S.
The risk of end-stage renal disease in patients with systemic lupus erythematosus may even be declining, but outcomes differ by race.
The condition appears to be associated with high hospitalization and death rates, researchers reported.
Half of those lupus nephritis patients taking three medications achieved full remission.
A plant-based compound could provide a new treatment for lupus nephritis with fewer side effects.
Large study looked at matched pairs of lupus patients with renal disease starting dialysis with hemodialysis or peritoneal dialysis.
With systemic lupus erythematosus, kidney disease reduces life expectancy an average of 15 years
Predictors of moderate-severe SLE flare at week 52 identified using three indicators
A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.
Do you think patients with lupus nephritis can be good renal transplant candidates if their disease has been quiescent for at least one year?February 15, 2013
In a recent study researchers examined transplant outcomes in patients with lupus nephritis who had no clinical evidence of disease in the year prior.
Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.
Genetic changes may partly explain why African-Americans with lupus are up to five times more likely develop end-stage kidney disease.
SLE patients with renal failure often continue to experience flares, but most commonly these are serologic rather than clinical.
If a lupus patient has never had renal disease, pregnancy, in and of itself, is not likely to increase that risk.
Even partial recovery in lupus nephritis patients lowers the risk of needing dialysis or a kidney transplant.
Effects of MMF may be influenced by the pathogenesis and/or cellular micro-environments unique to each disease process.
Approximately 30%-50% of SLE patients have clinically evident renal disease at presentation, but renal involvement occurs in up to 60% of patients overall.
The American College of Rheumatology (ACR) has issued new guidelines for screening, treating, and managing lupus nephritis (LN), including methods of identifying kidney disease, newer therapies, and pregnant patient care.
Adding rituximab to mycophenolate mofetil and corticosteroids does not improve outcomes in patients with lupus nephritis (LN), according to a study.
Black race is associated with worse renal transplant outcomes among patients with lupus nephritis and focal segmental glomerulosclerosis (FSGS), according to two studies presented at Kidney Week, the annual meeting of the American Society of Nephrology.
Mycophenolate mofetil (MMF) is more effective than azathioprine as maintenance therapy for patients with active lupus nephritis (LN) who responded to induction therapy, researchers reported.
CHICAGO—Adding abatacept to mycophenolate mofetil (MMF) and steroids does not significantly improve the time to complete renal response in patients with lupus nephritis (LN), according to the findings of a 12-month study presented at the 2011 American College of Rheumatology annual meeting.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)